Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPCN 1144 is an oral prodrug of bioidentical testosterone (specifically, testosterone undecanoate) developed by Lipocine for the treatment of pre-cirrhotic non-alcoholic steatohepatitis (NASH). It is designed to deliver testosterone via intestinal lymphatic absorption, bypassing first-pass liver metabolism. The drug acts as an androgen receptor agonist and functions as a hormonal replacement therapy. Clinical studies have shown that LPCN 1144 reduces liver fat content and improves markers of liver injury in hypogonadal males with NASH or NAFLD. The drug has demonstrated a favorable safety profile in Phase II trials, with improvements noted in steatosis, inflammation, and ballooning without worsening fibrosis[1][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LPCN 1144 (testosterone undecanoate).